| Company/Division name | Eli Lilly |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 750 |
| Year reshoring announced: | 2024 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 3000 |
| City reshored to: | Kenosha |
| State(s) reshored to: | WI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | injectable treatments |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Automation/technology |
